GUSTO III trial comparing Boehringer Mannheim's reteplase to Activase to begin in summer 1995.
Executive Summary
GUSTO III COMPARING RETEPLASE WITH ALTEPLASE TO BEGIN IN SUMMER OF 1995 enrolling 10,000 to 12,000 patients experiencing myocardial infarctions, Boehringer Mannheim reported March 20. The announcement by the manufacturer of reteplase, a novel modified recombinant plasminogen activator, came during the annual meeting of the American College of Cardiology in New Orleans.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth